Key result
Peripheral artery disease was associated with significantly lower BDNF serum concentrations compared to healthy controls (median 7.2 vs. 35.1 ng/mL), especially in patients with comorbid heart failure.
Why the study?
BDNF and the BDNF Val66Met polymorphism have been linked to cardiovascular diseases, but their connection to peripheral artery disease had not yet been described.
Case-Control (n=216)
Absolute Event Rate: 7.2% vs 35.1%
p-value: p=<0.001
Serum BDNF concentrations are significantly reduced in patients with peripheral artery disease, particularly those with comorbid heart failure, suggesting a link between cardiovascular burden and decreased BDNF.
Lower serum BDNF in PAD, especially with comorbid HF; extends observational links to atherosclerosis but leaves biomarker utility and polymorphism role open.
Introduction: Brain-derived neurotrophic factor (BDNF) and BDNF Val66Met polymorphism have been associated with cardiovascular diseases such as atherosclerosis, congestive heart failure (CHF), hypertension and ischaemic heart disease (IHD). To the authors’ knowledge, such connections have not been described in peripheral artery disease (PAD) yet. Material and methods: 159 PAD subjects and 57 controls were included. All enrolled subjects underwent evaluation of clinical status. Information on comorbidities such as diabetes type 2, hypertension, IHD and CHF, was gathered. Serum concentrations of BDNF were measured by ELISA. Genotypes of the BDNF-AS SNP rs6265 were determined using TaqMan SNP Genotyping Assay. Results: PAD patients had significantly lower BDNF serum concentrations compared to controls (median values of 7.2 vs. 35.1 ng/mL, P < 0.001). Concentrations were significantly lower in patients with concomitant CHF (P < 0.05). The CHF subgroup was characterised by a greater prevalence of diabetes and ischaemic heart disease (P < 0.01). There was no significant difference between BDNF serum concentrations and other comorbidities, ABI, and medical history including disease duration and past interventions. No important correlations were found for BDNF Val66Met polymorphism. Conclusions: The present study adds to the body of evidence associating BDNF and atherosclerosis. The serum BDNF concentrations were lower in PAD, especially in a subgroup with comorbid CHF. These results suggest that a larger cardiovascular burden is connected with decreased BDNF serum concentrations. No evidence was found to support the hypothesis that BDNF gene polymorphism may be a contributing factor in the pathogenesis of cardiovascular diseases such as PAD.
No takes yet. Share an insight, caveat, or question.
Chyrek-Tomaszewska et al. (2023) conducted a case-control in Peripheral artery disease (n=216). Peripheral artery disease vs. Healthy controls was evaluated on BDNF serum concentration (ng/mL) (p=<0.001). Peripheral artery disease was associated with significantly lower BDNF serum concentrations compared to healthy controls (median 7.2 vs. 35.1 ng/mL), especially in patients with comorbid heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: